Etomidate: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 66: | Line 66: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:57, 20 March 2026
See critical care quick reference for drug doses by weight.
General
- Type: Sedative
- Dosage Forms: IV
- Common Trade Names: Amidate, Tomvi
Adult Dosing
RSI
- 0.3mg/kg bolus IV
- Average: 20mg
- Consider half-dose (0.15mg/kg) for obtunded patients
Procedural Sedation
- 0.1mg/kg one time dosing
- Max: 10mg
- Minimal respiratory depression but decrease blood pressure and heart rate (alpha2 agonism)
Pediatric Dosing
See critical care quick reference for drug doses by weight.
- Children < 10 years
- 0.2-0.3 mg/kg IV
- Children > 10 years
- 0.3 mg/kg IV
Special Populations
- Pregnancy Rating: C
- Lactation: etomidate is present in breast milk
- Renal Dosing
- Adult
- Not defined however higher risk of toxicity with renal impairment
- Pediatric
- Not defined however higher risk of toxicity with renal impairment
- Adult
- Hepatic Dosing
- Adult
- Not defined
- Pediatric
- Not defined
- Adult
Contraindications
- Allergy to class/drug
Adverse Reactions
- Myoclonus
- Nausea/Vomiting
- Pain at injection site
- apnea
Controversy
- May suppress adrenal function in critically ill patient
- "The available evidence suggests that etomidate suppresses adrenal function transiently without
demonstrating a significant effect on mortality. However, no studies to date have been powered to detect a difference in hospital, ventilator, or ICU length of stay or in mortality."[1]
- Meta-analysis in 2023 showed increased mortality in critically ill patients
Pharmacology
- Half-life: 75 minutes
- Metabolism: Liver
- Excretion: Urine
- Mechanism of Action: GABA agonist
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Procedural sedation | 0.15 mg/kg | Procedural sedation | IV | Adult |
| Procedural sedation | 0.1-0.2 mg/kg | Procedural sedation (solo) | IV | Adult |
| Rapid sequence intubation | 0.2-0.4 mg/kg | Induction | IV | Adult |
See Also
References
- ↑ *Hohl CM, Kelly-Smith CH,Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of Etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med. 2010;56(2):105-113.
Etomidate: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.